Amit Dhudashiya

  • Citations Per Year
Learn More
Recent advances in achieving highly durable clinical responses via inhibition of immune checkpoint proteins including CTLA-4 and PD1 have revolutionized the outlook for cancer therapy. However, along with impressive clinical activity (response rate of ~25% with either antiCTLA-4 or anti-PD1 as single agent, but > 50% with a combination), severe(More)
  • 1